Docosahexaenoic and eicosapentaenoic acids increase neuronal death in response to HuPrP82-146 and Aβ1-42

Neuropharmacology

Volumn 54, Issue 6, 2008, Pages 934-943

  Bate, Clive ^a   Marshall, Victoria ^a   Colombo, Laura ^b   Diomede, Luisa ^b   Salmona, Mario ^b   Williams, Alun ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Cytoplasmic phospholipase A2; Lipid rafts; Neurotoxicity; Polyunsaturated fatty acids; Prion; Prostaglandins

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CASPASE 3; CAVEOLIN 1; CHOLESTEROL; DOCOSAHEXAENOIC ACID; FLUORESCEIN ISOTHIOCYANATE; ICOSAPENTAENOIC ACID; PHOSPHOLIPASE A2; PRION PROTEIN; PROSTAGLANDIN E2; PRP 82-146 PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; BRAIN CORTEX; CELL KINETICS; CELL LOSS; CELL SURVIVAL; CEREBELLUM; CONTROLLED STUDY; DRUG ACTIVITY; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; LIPID RAFT; MOUSE; NERVE CELL MEMBRANE; NERVE CELL NECROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION;

AMYLOID BETA-PROTEIN; ANIMALS; CASPASE 3; CAVEOLIN 1; CELL DEATH; CELLS, CULTURED; CHOLESTEROL; DINOPROSTONE; DOCOSAHEXAENOIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; EICOSAPENTAENOIC ACID; ENZYME-LINKED IMMUNOSORBENT ASSAY; MICE; NERVE TISSUE PROTEINS; NEURONS; PEPTIDE FRAGMENTS; PHOSPHOLIPASES A2; PRIONS;

EID: 41949090511     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2008.02.003     Document Type: Article

References (46)

1. Alberts A.W., Chen J., Kuron G., Hunt V., Huff J., Hoffman C., Rothrock J., Lopez M., Joshua H., Harris E., Patchett A., Monaghan R., Currie S., Stapley E., Albers-Schonberg G., Hensens O., Hirshfield J., Hoogsteen K., Liesch J., and Springer J. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc. Natl. Acad. Sci. U.S.A. 77 (1980) 3957-3961
2. Arndt R., Stark R., Klein P., Muller A., and Thiele H.G. Solubilization and molecular characterization of membrane-bound antigens shared by thymocytes and brain. Eur. J. Immunol. 6 (1976) 333-340
3. Bate C., Salmona M., Diomede L., and Williams A. Squalestatin cures prion-infected neurones and protects against prion neurotoxicity. J. Biol. Chem. 279 (2004) 14983-14990
4. Bate C., Salmona M., and Williams A. The role of platelet activating factor in prion and amyloid-β neurotoxicity. Neuroreport 15 (2004) 509-513
5. Bate C., and Williams A. Squalestatin protects neurons and reduces the activation of cytoplasmic phospholipase A2 by A[beta]1-42. Neuropharmacology 53 (2007) 222-231
6. Brandner S., Isenmann S., Raeber A., Fischer M., Sailer A., Kobayashi Y., Marino S., Weissmann C., and Aguzzi A. Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature 379 (1996) 339-343
7. Bueler H., Aguzzi A., Sailer A., Greiner R.A., Autenried P., Aguet M., and Weissmann C. Mice devoid of PrP are resistant to scrapie. Cell 73 (1993) 1339-1347
8. Calleros L., Lasa M., Rodriguez-Alvarez F.J., Toro M.J., and Chiloeches A. RhoA and p38 MAPK mediate apoptosis induced by cellular cholesterol depletion. Apoptosis 11 (2006) 1161-1173
9. Fai Mok S.W., Thelen K.M., Riemer C., Bamme T., Gultner S., Lutjohann D., and Baier M. Simvastatin prolongs survival times in prion infections of the central nervous system. Biochem. Biophys. Res. Commun. 348 (2006) 697-702
10. Farooqui A.A., Horrocks L.A., and Farooqui T. Deacylation and reacylation of neural membrane glycerophospholipids. J. Mol. Neurosci. 14 (2000) 123-135
11. Fioriti L., Angeretti N., Colombo L., De Luigi A., Colombo A., Manzoni C., Morbin M., Tagliavini F., Salmona M., Chiesa R., and Forloni G. Neurotoxic and gliotrophic activity of a synthetic peptide homologous to Gerstmann-Straussler-Scheinker disease amyloid protein. J. Biol. Chem. 27 (2007) 1576-1583
12. Florent S., Malaplate-Armand C., Youssef I., Kriem B., Koziel V., Escanye M.C., Fifre A., Sponne I., Leininger-Muller B., Olivier J.-L., Pillot T., and Oster T. Docosahexaenoic acid prevents neuronal apoptosis induced by soluble amyloid-beta oligomers. J. Neurochem. 96 (2006) 385-395
13. Fowler K.H., Chapkin R.S., and McMurray D.N. Effects of purified dietary n-3 ethyl esters on murine T lymphocyte function. J. Immunol. 151 (1993) 5186-5197
14. Garcia-Pelayo M.C., Garcia-Peregrin E., and Martinez-Cayuela M. Differential translational effects of myristic acid and eicosapentaenoic acid on 3-hydroxy-3-methylglutaryl-CoA reductase from Reuber H35 hepatoma cells. Exp. Biol. Med. 229 (2004) 781-786
15. Graziani A., Bricko V., Carmignani M., Graier W.F., and Groschner K. Cholesterol- and caveolin-rich membrane domains are essential for phospholipase A(2)-dependent EDHF formation. Cardiovasc. Res. 64 (2004) 234-242
16. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
17. Kempster S., Bate C., and Williams A. Simvastatin treatment prolongs the survival of scrapie-infected mice. Neuroreport 18 (2007) 479-482
18. Klein W.L., Krafft G.A., and Finch C.E. Targeting small A[beta] oligomers: the solution to an Alzheimer's disease conundrum?. Trends Neurosci. 24 (2001) 219-224
19. Kriem B., Sponne I., Fifre A., Malaplate-Armand C., Lozac'h-Pillot K., Koziel V., Yen-Potin F.T., Bihain B., Oster T., Olivier J.-L., and Pillot T. Cytosolic phospholipase A2 mediates neuronal apoptosis induced by soluble oligomers of the amyloid-β peptide. FASEB J. (2004)
20. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., and Klein W.L. Diffusible, nonfibrillar ligands derived from Abeta 1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 6448-6453
21. Liu J., Takano T., Papillon J., Khadir A., and Cybulsky A.V. Cytosolic phospholipase A2-alpha associates with plasma membrane, endoplasmic reticulum and nuclear membrane in glomerular epithelial cells. Biochem. J. 353 (2001) 79-90
22. Lorenzo A., and Yankner B.A. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 12243-12247
23. Luchsinger J.A., and Mayeux R. Dietary factors and Alzheimer's disease. Lancet Neurol. 3 (2004) 579-587
24. Ma D.W.L., Seo J., Davidson L.A., Callaway E.S., Fan Y.Y., Lupton J.R., and Chapkin R.S. n-3 PUFA Alter caveolae lipid composition and resident protein localization in mouse colon. FASEB J. 18 (2004) 1040-1042
25. 2-dependent sphingomyelinase-ceramide pathway. Neurobiol. Dis. 23 (2006) 178-189
26. Mallucci G., Dickinson A., Linehan J., Klohn P.C., Brandner S., and Collinge J. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 302 (2003) 871-874
27. Mukherjee P.K., Marcheselli V.L., Serhan C.N., and Bazan N.G. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc.Natl.Acad.Sci.U.S.A. (2004) 8491-8496
28. Muller W.E., Ushijima H., Schroder H.C., Forrest J.M., Schatton W.F., Rytik P.G., and Heffner-Lauc M. Cytoprotective effect of NMDA receptor antagonists on prion protein (PrionSc)-induced toxicity in rat cortical cell cultures. Eur. J. Pharmacol. 246 (1993) 261-267
29. Pan K.M., Baldwin M., Nguyen J., Gasset M., Serban A., Groth D., Mehlhorn I., Huang Z., Fletterick R.J., and Cohen F.E. Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 10962-10966
30. Pike C.J., Burdick D., Walencewicz A.J., Glabe C.G., and Cotman C.W. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13 (1993) 1676-1687
31. Pike L.J. Lipid rafts: heterogeneity on the high seas. Biochem. J. 378 (2004) 281-292
32. Prusiner S.B. Prions. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 13363-13383
33. Rothberg K.G., Ying Y.S., Kamen B.A., and Anderson R.G. Cholesterol controls the clustering of the glycophospholipid-anchored membrane receptor for 5-methyltetrahydrofolate. J. Cell Biol. 111 (1990) 2931-2938
34. Rottkamp C.A., Atwood C.S., Joseph J.A., Nunomura A., Perry G., and Smith M.A. The state versus amyloid-[beta]: the trial of the most wanted criminal in Alzheimer disease. Peptides 23 (2002) 1333-1341
35. Salmona M., Morbin M., Massignan T., Colombo L., Mazzoleni G., Capobianco R., Diomede L., Thaler F., Mollica L., Musco G., Kourie J.J., Bugiani O., Sharma D., Inouye H., Kirschner D.A., Forloni G., and Tagliavini F. Structural properties of Gerstmann-Straussler-Scheinker disease amyloid protein. J. Biol. Chem. 278 (2003) 48146-48153
36. Schroeder F., Gallegos A.M., Atshaves B.P., Storey S.M., McIntosh A.L., Petrescu A.D., Huang H., Starodub O., Chao H., Yang H., Frolov A., and Kier A.B. Recent advances in membrane micro-domains: rafts, caveolae, and intracellular cholesterol trafficking. Exp. Biol. Med. 226 (2001) 873-890
37. Serhan N. Novel [omega]-3-derived local mediators in anti-inflammation and resolution. Pharmacol. Ther. 105 (2005) 7-21
38. Siddiqui R.A., Shaikh S.R., Sech L.A., Yount H.R., Stillwell W., and Zaloga G.P. Omega 3-fatty acids: health benefits and cellular mechanisms of action. Mini. Rev. Med. Chem. 4 (2004) 859-871
39. Simons K., and Ikonen E. Functional rafts in cell membranes. Nature 387 (1997) 569-572
40. Solfrizzi V., Colacicco A.M., D'Introno A., Capurso C., Torres F., Rizzo C., Capurso A., and Panza F. Dietary intake of unsaturated fatty acids and age-related cognitive decline: a 8.5-year follow-up of the Italian Longitudinal Study on Aging. Neurobiol. Aging 27 (2006) 1694-1704
41. Stulnig T.M., Berger M., Sigmund T., Raederstorff D., Stockinger H., and Waldhausl W. Polyunsaturated fatty acids inhibit T cell signal transduction by modification of detergent-insoluble membrane domains. J. Cell Biol. 143 (1998) 637-644
42. Stulnig T.M., Huber J., Leitinger N., Imre E.M., Angelisova P., Nowotny P., and Waldhausl W. Polyunsaturated eicosapentaenoic acid displaces proteins from membrane rafts by altering raft lipid composition. J. Biol. Chem. 276 (2001) 37335-37340
43. Sun G.Y., Xu J., Jensen M.D., and Simonyi A. Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. J. Lipid Res. 45 (2004) 205-213
44. Sunyach C., Jen A., Deng J., Fitzgerald K.T., Frobert Y., Grassi J., McCaffrey M.W., and Morris R. The mechanism of internalization of glycosylphosphatidylinositol-anchored prion protein. EMBO J 22 (2003) 3591-3601
45. Tagliavini F., Prelli F., Ghiso J., Bugiani O., Serban D., Prusiner S.B., Farlow M.R., Ghetti B., and Frangione B. Amyloid protein of Gerstmann-Straussler-Scheinker disease (Indiana kindred) is an 11 kd fragment of prion protein with an N-terminal glycine at codon 58. EMBO J 10 (1991) 513-519
46. Tsui-Pierchala B.A., Encinas M., Milbrandt J., and Johnson Jr. E.M. Lipid rafts in neuronal signaling and function. Trends Neurosci. 25 (2002) 412-417